Velphoro Shortage Update: What Patients Need to Know in 2026

If you take Velphoro (sucroferric oxyhydroxide) for chronic kidney disease and have had trouble filling your prescription, you may be wondering: Is Velphoro actually in shortage? The answer is nuanced — and understanding it can help you take the right steps to get your medication.

Current Velphoro Shortage Status (2026)

As of 2026, Velphoro does not appear on the FDA's official Drug Shortages Database or the ASHP (American Society of Health-System Pharmacists) shortage list. Fresenius Medical Care, the manufacturer, has not reported manufacturing or supply disruptions for sucroferric oxyhydroxide.

However, there is a real and growing access problem — one that is structural rather than supply-driven. Dialysis patients who need Velphoro are running into barriers for reasons that have nothing to do with manufacturing capacity. Here's why.

Why Patients Are Struggling to Find Velphoro

1. The 2025 Medicare ESRD PPS Change Created Confusion
As of January 1, 2025, phosphate binders like Velphoro became included in the Medicare ESRD Prospective Payment System (PPS). This means most Medicare dialysis patients no longer fill Velphoro at a retail pharmacy — their dialysis center provides it. But the transition created confusion: some patients don't know this has changed, some centers haven't fully implemented the new system, and some patients fall outside the PPS (commercial insurance, certain Medicare Advantage plans, pending Medicare eligibility).

2. Retail Pharmacies Rarely Stock Velphoro
Velphoro has never been a mainstream retail pharmacy drug. Because it is exclusively for dialysis patients, most CVS, Walgreens, and Walmart pharmacies simply don't order it. Patients who call their local pharmacy and can't find it may incorrectly assume there's a shortage.

3. No Generic Means Limited Distribution Channels
With no generic version available (and none expected until at least July 2030 when the earliest patent expires), Velphoro remains a single-source brand-name drug. Distribution is tightly controlled through specialty and dialysis-center channels rather than the broader retail network.

4. Prior Authorization Delays
For patients who do fill through a pharmacy, most commercial insurance plans and Medicare Part D plans require prior authorization and step therapy (proving you've tried calcium acetate first). These PA delays — sometimes taking days or weeks — can leave patients without their medication.

What Has Changed With Velphoro Access Over Time?

Velphoro was FDA-approved in November 2013. When it first came to market, it was hailed as a major improvement over existing phosphate binders because of its dramatically lower pill burden — patients could take just 1 tablet per meal instead of 3-4 tablets with sevelamer.

Over the years, Velphoro became a standard part of many dialysis centers' formularies. However, its brand-name-only status and high cash price have always made access difficult for patients outside standard ESRD channels. The 2025 ESRD PPS change was meant to streamline access for Medicare patients — but it created new friction for those outside that system.

What Patients Should Do Right Now

1. If you're on Medicare ESRD: Ask your dialysis center why you're not getting Velphoro through your facility. As of 2025, it should be included at no additional cost.

2. If you have commercial insurance: Ask your nephrologist to initiate prior authorization and use the Velphoro Savings Card (up to $1,500 savings, $0 copay). Call Velphoro Concierge Support at 888-222-5270.

3. If you're uninsured: Apply for Velphoro Access Solutions (Fresenius Medical Care's PAP) or explore Prescription Hope ($70/month service fee). At $2,000+/month retail, your nephrologist may bridge you with generic sevelamer in the meantime.

4. If you can't find Velphoro at any pharmacy:[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop calls pharmacies near you to find which ones have it in stock and can fill your prescription.

Do Not Skip Doses If Velphoro Is Unavailable

High phosphorus levels are dangerous in dialysis patients. Uncontrolled hyperphosphatemia increases the risk of vascular calcification, bone disease, heart attack, and death. If you cannot get Velphoro, call your nephrologist immediately. They can bridge you with another phosphate binder like sevelamer or calcium acetate so that your phosphorus control is not interrupted.

See our guide to Velphoro alternatives for dialysis patients for a full comparison of your options.